Literature DB >> 24583243

Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions.

Matthew W Parker1, Craig W Vander Kooi2.   

Abstract

Vascular endothelial growth factor-C (VEGF-C) is a secreted growth factor essential for lymphangiogenesis. VEGF-C functions in both physiological and pathological lymphangiogenesis, particularly in tumor metastasis, making it an attractive therapeutic target. Members of two families of cell surface receptors transduce VEGF-C signals: neuropilin-2 (Nrp2) and VEGF-receptor (VEGFR)-2/3. Nrp2 is a promising target for inhibition because it is highly expressed in lymphatic vessels. Here we describe a microplate-based assay for discovery of VEGF-C/Nrp2 inhibitors. We optimize this assay for use in screening an inhibitor library and identify three novel Nrp2/VEGF-C binding inhibitors from the National Institutes of Health (NIH) Clinical Collection small molecule library.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assay; Inhibitor; Ligand; Neuropilin; Receptor; VEGF

Mesh:

Substances:

Year:  2014        PMID: 24583243      PMCID: PMC4036672          DOI: 10.1016/j.ab.2014.02.017

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  18 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Transient mammalian cell transfection with polyethylenimine (PEI).

Authors:  Patti A Longo; Jennifer M Kavran; Min-Sung Kim; Daniel J Leahy
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

Review 3.  The role of neuropilins in cancer.

Authors:  Lee M Ellis
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

4.  Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin.

Authors:  Matthew W Parker; Lance M Hellman; Ping Xu; Michael G Fried; Craig W Vander Kooi
Journal:  Biochemistry       Date:  2010-05-18       Impact factor: 3.162

5.  Mechanistic basis for the potent anti-angiogenic activity of semaphorin 3F.

Authors:  Hou-Fu Guo; Xiaobo Li; Matthew W Parker; Johannes Waltenberger; Patrice M Becker; Craig W Vander Kooi
Journal:  Biochemistry       Date:  2013-10-18       Impact factor: 3.162

6.  Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.

Authors:  Anna Starzec; Roger Vassy; Antoine Martin; Marc Lecouvey; Mélanie Di Benedetto; Michel Crépin; Gérard Y Perret
Journal:  Life Sci       Date:  2006-08-16       Impact factor: 5.037

7.  Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex.

Authors:  Anna Starzec; Patrick Ladam; Roger Vassy; Sabah Badache; Nadia Bouchemal; Alda Navaza; Catherine Hervé du Penhoat; Gérard Y Perret
Journal:  Peptides       Date:  2007-09-29       Impact factor: 3.750

Review 8.  Function of members of the neuropilin family as essential pleiotropic cell surface receptors.

Authors:  Matthew W Parker; Hou-Fu Guo; Xiaobo Li; Andrew D Linkugel; Craig W Vander Kooi
Journal:  Biochemistry       Date:  2012-11-14       Impact factor: 3.162

9.  Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition.

Authors:  Matthew W Parker; Ping Xu; Hou-Fu Guo; Craig W Vander Kooi
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

Review 10.  Tumor angiogenesis factor. Speculations on an approach to cancer chemotherapy.

Authors:  N Blumberg
Journal:  Yale J Biol Med       Date:  1974
View more
  6 in total

1.  Deletion of neuropilin 2 enhances detrusor contractility following bladder outlet obstruction.

Authors:  Evalynn Vasquez; Vivian Cristofaro; Stefan Lukianov; Fiona C Burkhard; Ali Hashemi Gheinani; Katia Monastyrskaya; Diane R Bielenberg; Maryrose P Sullivan; Rosalyn M Adam
Journal:  JCI Insight       Date:  2017-02-09

2.  Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form.

Authors:  Matthew W Parker; Andrew D Linkugel; Hira Lal Goel; Tingting Wu; Arthur M Mercurio; Craig W Vander Kooi
Journal:  Structure       Date:  2015-03-05       Impact factor: 5.006

Review 3.  The non-canonical role of vascular endothelial growth factor-C axis in cancer progression.

Authors:  Chu-An Wang; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-16

Review 4.  Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance.

Authors:  Ridwan Islam; Juhi Mishra; Sanika Bodas; Sreyashi Bhattacharya; Surinder K Batra; Samikshan Dutta; Kaustubh Datta
Journal:  Cancer Metastasis Rev       Date:  2022-07-01       Impact factor: 9.237

5.  Design, synthesis, and evaluation of a novel benzamidine-based inhibitor of VEGF-C binding to Neuropilin-2.

Authors:  Ahmed M Said; Matthew W Parker; Craig W Vander Kooi
Journal:  Bioorg Chem       Date:  2020-04-16       Impact factor: 5.307

6.  MiR-377-3p inhibits atherosclerosis-associated vascular smooth muscle cell proliferation and migration via targeting neuropilin2.

Authors:  Haijun Wang; Zheng Wei; Hulun Li; Yinghui Guan; Zhiyang Han; Hengzhen Wang; Bing Liu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.